Loading
Life sciences · Journal article
Frontiers in Genetics · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Genomic technologies are widely applied clinically to identify pathogens and their antimicrobial susceptibilities, but less use is made of patients’ germline genomic variations in infectious disease management. Not only can inborn errors of immunity (IEIs), most of which are rare, be detected before severe complications develop, but host genomics can assist with risk stratification for severe common infections, antimicrobial therapy selection, and pharmacogenomic-guided dosing. Over 30 clinical immunologists, infectious disease specialists and geneticists met to outline challenges and opportunities concerning host genomics and infectious diseases. Obstacles identified included payer requirements for extensive conventional diagnostics prior to genetic testing, lack of electronic health record (EHR) interoperability, and limited evidence of efficacy and cost-effectiveness given the individual rarity of most IEIs. Priorities to broaden the use of host genomics include publicizing indicators of IEIs, building them into EHR informatics systems, and promoting multidisciplinary approaches to identifying patients with IEIs.